Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention

Journal of Alzheimer's Disease

Volumn 48, Issue 2, 2015, Pages 411-424

  Keeney, Jeriel Thomas Richard ^a   Ibrahimi, Shaher ^a   Zhao, Liqin ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Alzheimer's disease; apolipoprotein E2; apolipoprotein E3; apolipoprotein E4; early intervention; glucose metabolism; glucose transporter 4; insulin degrading enzyme; insulin like growth factor 1; peroxisome proliferator activated receptor gamma

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; GLUCOSE; GLUCOSE TRANSPORTER 4; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN KINASE B; SOMATOMEDIN C; APOLIPOPROTEIN E; INSULIN RECEPTOR SUBSTRATE; RNA; SLC2A4 PROTEIN, MOUSE; SOMATOMEDIN;

ADULT; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EARLY INTERVENTION; ENERGY YIELD; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; HIPPOCAMPUS; MIDDLE AGED; MOUSE; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; BRAIN; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; SEXUAL DEVELOPMENT; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; BRAIN; FEMALE; GENE EXPRESSION; GLUCOSE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; MICE, INBRED C57BL; MICE, TRANSGENIC; RNA; SEX CHARACTERISTICS; SOMATOMEDINS;

EID: 84941275337     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150348     Document Type: Article

References (100)

1. Holtzman DM, Morris JC, Goate AM (2011) Alzheimer's disease: The challenge of the second century. Sci Transl Med 3, 77sr71.
2. Thies W, Bleiler L (2013) 2013 Alzheimer's disease facts and figures. Alzheimers Dement 9, 208-245.
3. (2014) 2014 Alzheimer's disease facts and figures. Alzheimers Dement 10, e47-92.
4. Alzheimer's Disease Education&Referral Center (National Institute on Aging) (2008) Alzheimer's disease fact sheet, Alzheimer's Disease Education & Referral (ADEAR) Center, Silver Spring, MD.
5. Mullard A (2012) Sting of Alzheimer's failures offset by upcoming prevention trials. Nat Rev Drug Discov 11, 657-660.
6. Mosconi L (2005) Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 32, 486-510.
7. Aluise CD, Robinson RA, Beckett TL, Murphy MP, Cai J, Pierce WM, Markesbery WR, Butterfield DA (2010) Preclinical Alzheimer disease: Brain oxidative stress, Abeta peptide and proteomics. Neurobiol Dis 39, 221-228.
8. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, Phelps CH (2011) Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 280-292.
9. Mosconi L, Sorbi S, de Leon MJ, Li Y, Nacmias B, Myoung PS, Tsui W, Ginestroni A, Bessi V, Fayyazz M, Caffarra P, Pupi A (2006) Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 47, 1778-1786.
10. Jack CR Jr, Albert MS, Knopman DS, McKhann GM, Sperling RA, Carrillo MC, Thies B, Phelps CH (2011) Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7, 257-262.
11. Liu CC, Kanekiyo T, Xu H, Bu G (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol 9, 106-118.
12. Dorey E, Chang N, Liu QY, Yang Z, Zhang W (2014) Apolipoprotein E, amyloid-beta, and neuroinflammation in Alzheimer's disease. Neurosci Bull 30, 317-330.
13. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
14. Seripa D, D'Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A (2011) The genetics of the human APOE polymorphism. Rejuvenation Res 14, 491-500.
15. Lambotte C (1981) Biochemical polymorphism in man - its relation to disease. Anim Blood Groups Biochem Genet 12, 149-166.
16. Zannis VI, Breslow JL (1981) Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 20, 1033-1041.
17. Suarez BK, Schonfeld G (1981) Characterization of apolipoprotein E (ApoE) apoprotein levels in the various ApoE phenotypes. J Clin Endocrinol Metab 53, 435-438.
18. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Roses AD, Pericak-Vance MA, Small GW, Haines JL (1995) The apolipoprotein E E4 allele and sex-specific risk of Alzheimer's disease. JAMA273, 373-374.
19. Lambert JC, Perez-Tur J, Dupire MJ, Galasko D, Mann D, Amouyel P, Hardy J, Delacourte A, Chartier-Harlin MC (1997) Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet 6, 2151-2154.
20. Kim J, Basak JM, Holtzman DM (2009) The role of apolipoprotein E in Alzheimer's disease. Neuron 63, 287-303.
21. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, Rimmler JB, Locke PA, Conneally PM, Schmader KE, et al. (1994) Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 7, 180-184.
22. Frieden C, Garai K (2012) Structural differences between apoE3 and apoE4 may be useful in developing therapeutic agents for Alzheimer's disease. Proc Natl Acad Sci U S A 109, 8913-8918.
23. Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM (2014) ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease. Neuroimage Clin 4, 461-472.
24. Aleshkov S, Abraham CR, Zannis VI (1997) Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40). Relevance to Alzheimer's disease. Biochemistry 36, 10571-10580.
25. Payami H, Zareparsi S, Montee KR, Sexton GJ, Kaye JA, Bird TD, Yu CE, Wijsman EM, Heston LL, Litt M, Schellenberg GD (1996) Gender difference in apolipoprotein E-associated risk for familial Alzheimer disease: A possible clue to the higher incidence of Alzheimer disease in women. Am J Hum Genet 58, 803-811.
26. Mortensen EL, Hogh P (2001) A gender difference in the association between APOE genotype and age-related cognitive decline. Neurology 57, 89-95.
27. Anttila T, Helkala EL, Kivipelto M, Hallikainen M, Alhainen K, Heinonen H, Mannermaa A, Tuomilehto J, Soininen H, Nissinen A (2002) Midlife income, occupation, APOE status, and dementia: A population-based study. Neurology 59, 887-893.
28. Qiu C, Kivipelto M, Aguero-Torres H, Winblad B, Fratiglioni L (2004) Risk and protective effects of the APOE gene towards Alzheimer's disease in the Kungsholmen project: Variation by age and sex. J Neurol Neurosurg Psychiatry 75, 828-833.
29. Johnson JK, McCleary R, Oshita MH, Cotman CW (1998) Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E, age, and gender profiles. Brain Res 798, 18-24.
30. Risacher SL, Kim S, Shen L, Nho K, Foroud T, Green RC, Petersen RC, Jack CR Jr, Aisen PS, Koeppe RA, Jagust WJ, Shaw LM, Trojanowski JQ, Weiner MW, Saykin AJ (2013) The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci 5, 11.
31. Castellano JM, Kim J, Stewart FR, Jiang H, DeMattos RB, Patterson BW, Fagan AM, Morris JC, Mawuenyega KG, Cruchaga C, Goate AM, Bales KR, Paul SM, Bateman RJ, Holtzman DM (2011) Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci Transl Med 3, 89ra57.
32. Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, Holtzman DM, Zlokovic BV (2008) apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest 118, 4002-4013.
33. Yu JT, Tan L, Hardy J (2014) Apolipoprotein E in Alzheimer's disease: An update. Annu Rev Neurosci 37, 79-100.
34. Lauderback CM, Kanski J, Hackett JM, Maeda N, Kindy MS, Butterfield DA (2002) Apolipoprotein E modulates Alzheimer's Abeta(1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Res 924, 90-97.
35. Jiang Q, Lee CY, Mandrekar S, Wilkinson B, Cramer P, Zelcer N, Mann K, Lamb B, Willson TM, Collins JL, Richardson JC, Smith JD, Comery TA, Riddell D, Holtzman DM, Tontonoz P, Landreth GE (2008) ApoE promotes the proteolytic degradation of Abeta. Neuron 58, 681-693.
36. Cerf E, Gustot A, Goormaghtigh E, Ruysschaert JM, Raussens V (2011) High ability of apolipoprotein E4 to stabilize amyloid-beta peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J25, 1585-1595.
37. Hashimoto T, Serrano-Pozo A, Hori Y, Adams KW, Takeda S, Banerji AO, Mitani A, Joyner D, Thyssen DH, Bacskai BJ, Frosch MP, Spires-Jones TL, Finn MB, Holtzman DM, Hyman BT (2012) Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J Neurosci 32, 15181-15192.
38. Chiang GC, Insel PS, Tosun D, Schuff N, Truran-Sacrey D, Raptentsetsang ST, Jack CR Jr, Aisen PS, Petersen RC, Weiner MW (2010) Hippocampal atrophy rates and CSF biomarkers in elderly APOE2 normal subjects. Neurology 75, 1976-1981.
39. Caselli RJ, Dueck AC (2010) APOE varepsilon2 and presymptomatic stage Alzheimer disease: How much is not enough? Neurology 75, 1952-1953.
40. Small GW, Mazziotta JC, Collins MT, Baxter LR, Phelps ME, Mandelkern MA, Kaplan A, La Rue A, Adamson CF, Chang L, et al. (1995) Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA273, 942-947.
41. Pedros I, Petrov D, Allgaier M, Sureda F, Barroso E, Beas-Zarate C, Auladell C, Pallas M, Vazquez-Carrera M, Casadesus G, Folch J, Camins A (2014) Early alterations in energy metabolism in the hippocampus of APPSwe/PS1dE9 mouse model of Alzheimer's disease. Biochim Biophys Acta 1842, 1556-1566.
42. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 106, 14670-14675.
43. Liu Y, Yu JT, Wang HF, Han PR, Tan CC, Wang C, Meng XF, Risacher SL, Saykin AJ, Tan L (2015) APOE genotype and neuroimaging markers of Alzheimer's disease: Systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 86, 127-134.
44. de la Monte SM, Wands JR (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2, 1101-1113.
45. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7, 63-80.
46. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, Fuino RL, Kawaguchi KR, Samoyedny AJ, Wilson RS, Arvanitakis Z, Schneider JA, Wolf BA, Bennett DA, Trojanowski JQ, Arnold SE (2012) Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest 122, 1316-1338.
47. Zhang B, Tang XC, Zhang HY (2013) Alternations of central insulin-like growth factor-1 sensitivity in APP/PS1 transgenic mice and neuronal models. J Neurosci Res 91, 717-725.
48. Zhao WQ, Lacor PN, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 284, 18742-18753.
49. Bassil F, Fernagut PO, Bezard E, Meissner WG (2014) Insulin, IGF-1 and GLP-1 signaling in neurodegenerative disorders: Targets for disease modification? Prog Neurobiol 118, 1-18.
50. Wang W, Yu JT, Tan L, Liu QY, Wang HF, Ma XY (2012) Insulin-like growth factor 1 (IGF1) polymorphism is associated with Alzheimer's disease in Han Chinese. Neurosci Lett 531, 20-23.
51. Vargas T, Martinez-Garcia A, Antequera D, Vilella E, Clarimon J, Mateo I, Sanchez-Juan P, Rodriguez-Rodriguez E, Frank A, Rosich-Estrago M, Lleo A, Molina-Porcel L, Blesa R, Gomez-Isla T, Combarros O, Bermejo-Pareja F, Valdivieso F, Bullido MJ, Carro E (2011) IGF-I gene variability is associated with an increased risk for AD. Neurobiol Aging 32, 556 e553-511.
52. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH, Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272, 17972-17980.
53. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3, 1101-1108.
54. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162, 313-319.
55. Ong QR, Chan ES, Lim ML, Wong BS (2014) Expression of human apolipoprotein E4 reduces insulin-receptor substrate 1 expression and Akt phosphorylation in the ageing liver. FEBS Open Bio 4, 260-265.
56. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, de Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging 36, 811-822.
57. Forster S, Grimmer T, Miederer I, Henriksen G, Yousefi BH, Graner P, Wester HJ, Forstl H, Kurz A, Dickerson BC, Bartenstein P, Drzezga A (2012) Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay. Biol Psychiatry 71, 792-797.
58. Nordberg A, Rinne JO, Kadir A, Langstrom B (2010) The use of PET in Alzheimer disease. Nat Rev Neurol 6, 78-87.
59. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I, Wall A, Ringheim A, Langstrom B, Nordberg A (2006) Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 129, 2856-2866.
60. McRory JE, Sherwood NM (1997) Ancient divergence of insulin and insulin-like growth factor. DNA Cell Biol 16, 939-949.
61. Cholerton B, Baker LD, Craft S (2013) Insulin, cognition, and dementia. Eur J Pharmacol 719, 170-179.
62. Torres-Aleman I (2010) Toward a comprehensive neurobiology of IGF-I. Dev Neurobiol 70, 384-396.
63. Brooker GJ, Kalloniatis M, Russo VC, Murphy M, Werther GA, Bartlett PF (2000) Endogenous IGF-1 regulates the neuronal differentiation of adult stem cells. J Neurosci Res 59, 332-341.
64. Liu W, Ye P, O'Kusky JR, D'Ercole AJ (2009) Type 1 insulin-like growth factor receptor signaling is essential for the development of the hippocampal formation and dentate gyrus. J Neurosci Res 87, 2821-2832.
65. Aberg MA, Aberg ND, Hedbacker H, Oscarsson J, Eriksson PS (2000) Peripheral infusion of IGF-I selectively induces neurogenesis in the adult rat hippocampus. J Neurosci 20, 2896-2903.
66. Kurochkin IV (2001) Insulin-degrading enzyme: Embarking on amyloid destruction. Trends Biochem Sci 26, 421-425.
67. Miglio G, Rosa AC, Rattazzi L, Collino M, Lombardi G, Fantozzi R (2009) PPARgamma stimulation promotes mitochondrial biogenesis and prevents glucose deprivation-induced neuronal cell loss. Neurochem Int 55, 496-504.
68. Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez G, Inestrosa NC, Bronfman M (2007) Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J Biol Chem 282, 37006-37015.
69. Summers SA, Birnbaum MJ (1997) A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake. Biochem Soc Trans 25, 981-988.
70. Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA (2000) Insulin-like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci U S A 97, 10236-10241.
71. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM (2007) Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis 12, 285-290.
72. Moloney AM, Griffin RJ, Timmons S, O'Connor R, Ravid R, O'Neill C (2010) Defects in IGF-1 receptor, insulin receptor and IRS-1/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling. Neurobiol Aging 31, 224-243.
73. Watson RT, Pessin JE (2001) Intracellular organization of insulin signaling and GLUT4 translocation. Recent Prog Horm Res 56, 175-193.
74. Bevan P (2001) Insulin signalling. J Cell Sci 114, 1429-1430.
75. Sarruf DA, Yu F, Nguyen HT, Williams DL, Printz RL, Niswender KD, Schwartz MW (2009) Expression of peroxisome proliferator-activated receptor-gamma in key neuronal subsets regulating glucose metabolism and energy homeostasis. Endocrinology 150, 707-712.
76. Ryan KK, Li B, Grayson BE, Matter EK, Woods SC, Seeley RJ (2011) A role for central nervous system PPARgamma in the regulation of energy balance. Nat Med 17, 623-626.
77. Semple RK, Chatterjee VK, O'Rahilly S (2006) PPAR gamma and human metabolic disease. J Clin Invest 116, 581-589.
78. Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM (2013) PPARgamma signaling and metabolism: The good, the bad and the future. Nat Med 19, 557-566.
79. Gavrilova O, Haluzik M, Matsusue K, Cutson JJ, Johnson L, Dietz KR, Nicol CJ, Vinson C, Gonzalez FJ, Reitman ML (2003) Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J Biol Chem 278, 34268-34276.
80. Chen YC, Wu JS, Tsai HD, Huang CY, Chen JJ, Sun GY, Lin TN (2012) Peroxisome proliferator-activated receptor gamma (PPAR-gamma) and neurodegenerative disorders. Mol Neurobiol 46, 114-124.
81. Morris AA (2005) Cerebral ketone body metabolism. J Inherit Metab Dis 28, 109-121.
82. Chikahisa S, Shimizu N, Shiuchi T, Sei H (2014) Ketone body metabolism and sleep homeostasis in mice. Neuropharmacology 79, 399-404.
83. Schonfeld P, Reiser G (2013) Why does brain metabolism not favor burning of fatty acids to provide energy? Reflections on disadvantages of the use of free fatty acids as fuel for brain. J Cereb Blood Flow Metab 33, 1493-1499.
84. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC (2009) Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: A randomized, doubleblind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 6, 31.
85. Kuo LE, Kitlinska JB, Tilan JU, Li L, Baker SB, Johnson MD, Lee EW, Burnett MS, Fricke ST, Kvetnansky R, Herzog H, Zukowska Z (2007) Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 13, 803-811.
86. Butterfield DA, Drake J, Pocernich C, Castegna A (2001) Evidence of oxidative damage in Alzheimer's disease brain: Central role for amyloid beta-peptide. Trends Mol Med 7, 548-554.
87. Swomley AM, Forster S, Keeney JT, Triplett J, Zhang Z, Sultana R, Butterfield DA (2014) Abeta, oxidative stress in Alzheimer disease: Evidence based on proteomics studies. Biochim Biophys Acta 1842, 1248-1257.
88. Hensley K, Carney JM, Mattson MP, Aksenova M, Harris M, Wu JF, Floyd RA, Butterfield DA (1994) A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: Relevance to Alzheimer disease. Proc Natl Acad Sci U S A 91, 3270-3274.
89. Findeis MA (2007) The role of amyloid beta peptide 42 in Alzheimer's disease. Pharmacol Ther 116, 266-286.
90. Carro E, Trejo JL, Gomez-Isla T, LeRoith D, Torres-Aleman I (2002) Serum insulin-like growth factor I regulates brain amyloid-beta levels. Nat Med 8, 1390-1397.
91. Sharma S, Prasanthi RPJ, Schommer E, Feist G, Ghribi O (2008) Hypercholesterolemia-induced Abeta accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol Dis 32, 426-432.
92. Carro E, Trejo JL, Gerber A, Loetscher H, Torrado J, Metzger F, Torres-Aleman I (2006) Therapeutic actions of insulin-like growth factor I on APP/PS2 mice with severe brain amyloidosis. Neurobiol Aging 27, 1250-1257.
93. Fan J, Donkin J, Wellington C (2009) Greasing the wheels of Abeta clearance in Alzheimer's disease: The role of lipids and apolipoprotein E. Biofactors 35, 239-248.
94. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precur sor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100, 4162-4167.
95. Morelli L, Llovera R, Gonzalez SA, Affranchino JL, Prelli F, Frangione B, Ghiso J, Castano EM (2003) Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem 278, 23221-23226.
96. Zhao L, Yao J, Mao Z, Chen S, Wang Y, Brinton RD (2011) 17beta-Estradiol regulates insulin-degrading enzyme expression via an ERbeta/PI3-K pathway in hippocampus: Relevance to Alzheimer's prevention. Neurobiol Aging 32, 1949-1963.
97. Eckman EA, Eckman CB (2005) Abeta-degrading enzymes: Modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem Soc Trans 33, 1101-1105.
98. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, Hersh LB, Thiele DL (2003) Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A 100, 6221-6226.
99. Haque R, Nazir A (2014) Insulin-degrading enzyme: A link between Alzheimer's and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets 13, 259-264.
100. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: Implications for Abeta-induced disorders. Neurobiol Aging 26, 645-654.